Nektar Therapeutics Inc (NKTR)

21.39
0.36 1.66
NASDAQ : Health Care
Prev Close 21.75
Open 21.73
Day Low/High 21.15 / 21.99
52 Wk Low/High 9.16 / 17.55
Volume 1.06M
Avg Volume 1.11M
Exchange NASDAQ
Shares Outstanding 156.33M
Market Cap 3.53B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

IntelliPharmaceuticals has a bio-equivalent to OxyContin, but says it is harder to tamper with. The pharma company is hoping to gain a recommendation from an FDA committee on Wednesday.

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.

Nektar Shares Boosted by Promising Results on Opioid Addiction Study

Nektar Shares Boosted by Promising Results on Opioid Addiction Study

NKTR-181 is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.

Nektar Announces Topline Data From Human Abuse Potential Study For NKTR-181, A First-in-Class Investigational Opioid To Treat Chronic Pain

Nektar Announces Topline Data From Human Abuse Potential Study For NKTR-181, A First-in-Class Investigational Opioid To Treat Chronic Pain

NKTR-181 shows significantly less abuse potential compared to oxycodone

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Huge profits could be on the doorstep for these hot breakout setups.

Nektar Therapeutics Announces Data Presentations At ASCO 2017

New NKTR-214 Data to be Highlighted at ASCO in Poster Presentation and at Investor Event

Warren Buffett's Wisdom: Cramer's 'Mad Money' Recap (Monday 5/8/17)

Warren Buffett's Wisdom: Cramer's 'Mad Money' Recap (Monday 5/8/17)

The Oracle of Omaha believes in the future of U.S. business, says Jim Cramer. Plus, Buffett can admit his mistakes and we can learn from that.

First Week of June 16th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new June 16th contracts and identified one put and one call contract of particular interest.

Nektar Therapeutics Presents New Preclinical Data For Its Immuno-Oncology Programs At The American Association For Cancer Research (AACR) Annual Meeting

Five Data Presentations Showcased Nektar's Immuno-Oncology Candidates, NKTR-214 and NKTR-255

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round

Jim Cramer is bullish on Nektar Therapeutics and Alkermes, as well as Verizon and Bank of America.

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.

Nektar Therapeutics Initiates Clinical Study Of NKTR-358, A First-in-Class Regulatory T Cell Stimulator, Being Developed For The Treatment Of Immune And Inflammatory Disorders

NKTR-358 is designed to correct the underlying immune system dysfunction common to many auto-immune diseases

Traders Are Aggressively Fading the Open

Traders Are Aggressively Fading the Open

But what will be most important is whether support stays strong and the buyers show interest in the afternoon.

Rev's Forum: Don't Just Sit There, Do Something!

Rev's Forum: Don't Just Sit There, Do Something!

Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

Here's how to trade six of the most active names on the market this afternoon.

TheStreet Quant Rating: D- (Sell)